Shares of Sage Therapeutics Inc. (NASDAQ:SAGE) have been given a consensus recommendation of “Buy” by the thirteen research firms that are currently covering the firm. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eleven have given a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $75.50.

A number of equities research analysts have recently issued reports on the stock. Canaccord Genuity set a $110.00 price target on shares of Sage Therapeutics and gave the stock a “buy” rating in a report on Tuesday, September 6th. BMO Capital Markets reissued a “buy” rating and issued a $57.00 price target on shares of Sage Therapeutics in a report on Friday, August 12th. Stifel Nicolaus assumed coverage on shares of Sage Therapeutics in a report on Monday. They issued a “buy” rating and a $90.00 price target on the stock. Zacks Investment Research raised shares of Sage Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, August 26th. Finally, Cowen and Company reissued a “buy” rating on shares of Sage Therapeutics in a report on Monday, September 19th.

In other Sage Therapeutics news, CFO Kimi Iguchi sold 2,500 shares of the stock in a transaction that occurred on Wednesday, September 7th. The shares were sold at an average price of $40.93, for a total transaction of $102,325.00. Following the transaction, the chief financial officer now directly owns 81,239 shares in the company, valued at $3,325,112.27. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 5.60% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of SAGE. Teacher Retirement System of Texas boosted its position in shares of Sage Therapeutics by 38.2% in the second quarter. Teacher Retirement System of Texas now owns 3,522 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 973 shares during the last quarter. BNP Paribas Arbitrage SA boosted its position in shares of Sage Therapeutics by 129.1% in the third quarter. BNP Paribas Arbitrage SA now owns 2,369 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 1,335 shares in the last quarter. Legal & General Group Plc boosted its position in shares of Sage Therapeutics by 30.6% in the second quarter. Legal & General Group Plc now owns 5,414 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 1,268 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. purchased a new position in shares of Sage Therapeutics during the second quarter valued at about $208,000. Finally, Cowen Group Inc. purchased a new position in shares of Sage Therapeutics during the second quarter valued at about $211,000. Institutional investors and hedge funds own 85.82% of the company’s stock.

Shares of Sage Therapeutics (NASDAQ:SAGE) opened at 54.36 on Thursday. Sage Therapeutics has a 12-month low of $26.28 and a 12-month high of $62.64. The company’s market capitalization is $2.02 billion. The firm’s 50-day moving average is $44.40 and its 200-day moving average is $38.66.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported ($1.15) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.10) by $0.05. On average, equities analysts predict that Sage Therapeutics will post ($4.35) EPS for the current year.

Sage Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. Its lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor.

5 Day Chart for NASDAQ:SAGE

Receive News & Stock Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related stocks with our FREE daily email newsletter.